Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06618534 · ClinicalTrials.gov registry record · Phase 2
Azithromycin for Meningococcal Carriage
A Phase 2 study of Meningococcal Infections, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,120
- Enrollment target
- 1
- Study location
NCT06618534 is a Phase 2 study of Meningococcal Infections that is actively recruiting participants, run by Emory University. The registered enrollment target is 1,120 participants, above the 541-participant average among 4 other Meningococcal Infections trials with a reported enrollment target (107% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06618534, a Phase 2 study of Meningococcal Infections, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis
Conditions Studied
Interventions
- DRUG Azithromycin
Study Locations (1)
Georgia
- Hope Clinic of the Emory Vaccine Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,120 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06618534
The ClinicalTrials.gov registry entry for NCT06618534 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 541-participant average among 4 other Meningococcal Infections trials with a reported enrollment target (107% higher). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningococcal Infections appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.
NCT06618534 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06618534 about?
NCT06618534 is a clinical study titled "Azithromycin for Meningococcal Carriage". The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis
What is the current status of trial NCT06618534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,120 participants. The study started on 2024-11-12. Estimated completion is 2026-05.
What conditions does trial NCT06618534 study?
This clinical trial studies the following conditions: Meningococcal Infections.
What interventions are being tested in trial NCT06618534?
The interventions under investigation include: Azithromycin (DRUG).
Who is sponsoring clinical trial NCT06618534?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06618534 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningococcal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
COMPLETED · Phase 2
-
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
COMPLETED · Phase 1
-
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
COMPLETED · Phase 3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.